Journal article · 2026 · Open access
CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals
IAA Journal of Applied Sciences, 14(1), 1–5 · Published 16 March 2026 · DOI 10.59298/iaajas/2026/14115
In brief
“CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals” is a 2026 journal article by Mpora Kakwanzi Evelyn, published in IAA Journal of Applied Sciences. OpenAlex counts 0 citations as of 19 November 2026. It is open access: the full text is free to read at IAA Journal of Applied Sciences.
- Citations
- 0
- References
- 14
- Authors
- 1
Abstract
HIV persistence within latent reservoirs represents the principal barrier to cure despite lifelong antiretroviral therapy (ART). The CCR5 gene encodes a co-receptor essential for HIV-1 entry into CD4⁺ T cells, and individuals homozygous for the CCR5-Δ32 mutation exhibit natural resistance to infection. This observation has inspired therapeutic strategies to recreate this phenotype through gene editing. This review critically examined the translational and clinical evidence on CRISPR-Cas9-mediated CCR5 disruption as a potential functional cure strategy in HIV-infected individuals. A structured literature search of PubMed, Scopus, and ClinicalTrials.gov (2014–2025) identified peer-reviewed clinical and translational studies investigating CRISPR-Cas9-based CCR5 gene editing in human subjects living with HIV. CRISPR-Cas9 enables precise CCR5 knockout in autologous hematopoietic stem cells (HSCs) and CD4⁺ T cells, generating HIV-resistant progeny following transplantation or adoptive transfer. Early clinical trials demonstrated feasibility, with edited cells persisting and reconstituting immune function without major toxicity. However, editing efficiency, incomplete reservoir clearance, off-target effects, and limited engraftment restrict durable viral remission. Combinatorial approaches integrating latency-reversing agents or dual co-receptor targeting may enhance efficacy. CRISPR-Cas9 CCR5 gene editing offered a rational, biologically grounded path toward a functional HIV cure. Yet, translational success demands improved delivery systems, refined editing fidelity, and synergistic adjunctive strategies. Future human trials must prioritize long-term safety, durable reconstitution of HIV-resistant immunity, and reservoir eradication endpoints. Keywords: CRISPR-Cas9, CCR5, HIV functional cure, Gene editing, Hematopoietic stem cells
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Evelyn, M. K. (2026). CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals. IAA Journal of Applied Sciences, 14(1), 1–5. https://doi.org/10.59298/iaajas/2026/14115
MLA 9
Evelyn, Mpora Kakwanzi. “CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals.” IAA Journal of Applied Sciences, vol. 14, no. 1, 2026, pp. 1–5. https://doi.org/10.59298/iaajas/2026/14115.
Chicago
Evelyn, Mpora Kakwanzi. 2026. “CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals.” IAA Journal of Applied Sciences 14 (1): 1–5. https://doi.org/10.59298/iaajas/2026/14115.
Harvard
Evelyn, M. K. (2026) ‘CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals’, IAA Journal of Applied Sciences, 14(1), pp. 1–5. doi:10.59298/iaajas/2026/14115.
IEEE
M. K. Evelyn, “CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals,” IAA Journal of Applied Sciences, vol. 14, no. 1, pp. 1–5, 2026, doi: 10.59298/iaajas/2026/14115.
BibTeX
@article{evelyn2026crispr,
title = {{CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals}},
author = {Evelyn, Mpora Kakwanzi},
journal = {IAA Journal of Applied Sciences},
year = {2026},
volume = {14},
number = {1},
pages = {1--5},
doi = {10.59298/iaajas/2026/14115},
url = {https://doi.org/10.59298/iaajas/2026/14115}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- CRISPR/Cas9
- HIV latency
- latent viral reservoir
- CCR5 delta32 mutation
- hematopoietic stem cell gene therapy
- CD4+ T cells
- off-target effects
- latency-reversing agents
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Evelyn, M. K. (2026). CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals. IAA Journal of Applied Sciences, 14(1), 1–5. https://doi.org/10.59298/iaajas/2026/14115
How many times has this paper been cited?
0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at IAA Journal of Applied Sciences: sign in and open the PDF from this page.
Who wrote this paper?
Mpora Kakwanzi Evelyn.
What is the DOI of this paper?
10.59298/iaajas/2026/14115, permanently at https://doi.org/10.59298/iaajas/2026/14115. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.